Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis
暂无分享,去创建一个
A. Kasi | Weijing Sun | S. Chakrabarti | A. Chidharla | Samragnyi Madala | Kriti Agarwal | Brenda M. Linares | E. Rapoport
[1] P. Kasi,et al. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] J. Ptak,et al. Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer. , 2022, The New England journal of medicine.
[3] Dan Huang,et al. Postoperative circulating tumor DNA combined with consensus molecular subtypes can better predict outcomes in stage III colon cancers: A prospective cohort study. , 2022, European journal of cancer.
[4] Y. Jiao,et al. Response prediction and risk stratification of patients with rectal cancer after neoadjuvant therapy through an analysis of circulating tumour DNA , 2022, EBioMedicine.
[5] C. Andersen,et al. Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. , 2022, European journal of cancer.
[6] A. Knudsen,et al. Circulating tumor DNA for prognosis assessment and postoperative management after curative‐intent resection of colorectal liver metastases , 2022, International journal of cancer.
[7] A. Parikh,et al. Plasma-only ctDNA-Guided MRD Detection in Patients with CRC—Response , 2021, Clinical Cancer Research.
[8] Yan Peng,et al. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives , 2021, Frontiers in Oncology.
[9] K. Döhner,et al. 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.
[10] G. Chatellier,et al. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). , 2021, European journal of cancer.
[11] C. Andersen,et al. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences , 2021, Clinical Cancer Research.
[12] S. Chen,et al. 458P Circulating tumor DNA analysis predicting recurrence risk in patients with stage I-III colorectal cancer , 2021, Annals of Oncology.
[13] G. Meijer,et al. Postoperative circulating tumour DNA is associated with pathologic response and recurrence-free survival after resection of colorectal cancer liver metastases , 2021, EBioMedicine.
[14] S. Shchegrova,et al. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases , 2021, JCO precision oncology.
[15] M. Tzardi,et al. Resectable Colorectal Cancer: Current Perceptions on the Correlation of Recurrence Risk, Microbiota and Detection of Genetic Mutations in Liquid Biopsies , 2021, Cancers.
[16] C. Montagut,et al. ctDNA to Guide Adjuvant Therapy in Localized Colorectal Cancer (CRC) , 2021, Cancers.
[17] C. Andersen,et al. Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients. , 2021 .
[18] P. Ding,et al. Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer , 2021, Journal of Hematology & Oncology.
[19] E. Oki,et al. CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer , 2021, Cancer science.
[20] Jeffrey W. Clark,et al. Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer , 2021, Clinical Cancer Research.
[21] A. Feber,et al. Minimal residual disease (MRD) detection with circulating tumor DNA (ctDNA) from personalized assays in stage II-III colorectal cancer patients in a U.K. multicenter prospective study (TRACC). , 2021 .
[22] Jeffrey W. Clark,et al. Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer , 2021, JCO precision oncology.
[23] Huadan Xue,et al. Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study , 2020, Clinical Cancer Research.
[24] J. Ptak,et al. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies , 2020, International journal of cancer.
[25] A. Mahipal,et al. Early stage colon cancer: Current treatment standards, evolving paradigms, and future directions , 2020, World journal of gastrointestinal oncology.
[26] R. Labianca,et al. Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] O. W. Lindwasser,et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper , 2020, Nature Reviews Clinical Oncology.
[28] F. Liu,et al. The value of circulation tumor DNA in predicting postoperative recurrence of colorectal cancer: a meta-analysis , 2020, International Journal of Colorectal Disease.
[29] N. Wolmark,et al. NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer. , 2020 .
[30] Jeffrey W. Clark,et al. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers , 2020, Clinical Cancer Research.
[31] D. Tait,et al. MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer , 2019, Clinical Cancer Research.
[32] D. Moro,et al. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] J. Ptak,et al. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. , 2019, JAMA oncology.
[34] F. Papaccio,et al. Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype , 2019, Annals of Oncology.
[35] H. Nielsen,et al. Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.
[36] B. Chabner,et al. Application of Cell-free DNA Analysis to Cancer Treatment. , 2018, The New England journal of medicine.
[37] N. Nguyen,et al. Circulating tumor DNA and liquid biopsy: opportunities, challenges, and recent advances in detection technologies. , 2018, Lab on a chip.
[38] Maximilian Diehn,et al. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. , 2018, Archives of pathology & laboratory medicine.
[39] K. Kinzler,et al. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study , 2018, Gut.
[40] M. Brüggemann,et al. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. , 2017, Hematology. American Society of Hematology. Education Program.
[41] M. Brüggemann,et al. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. , 2017, Blood advances.
[42] H. Nielsen,et al. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer , 2017, Clinical Cancer Research.
[43] S. Mortimer,et al. Circulating tumor DNA (ctDNA) utilizing a high-sensitivity panel to detect minimal residual disease post liver hepatectomy and predict disease recurrence. , 2017 .
[44] Ash A. Alizadeh,et al. Early prediction of clinical outcomes in resected stage II and III colorectal cancer (CRC) through deep sequencing of circulating tumor DNA (ctDNA). , 2017 .
[45] Joseph Kannarkatt,et al. Adjuvant Chemotherapy for Stage II Colon Cancer: A Clinical Dilemma. , 2017, Journal of oncology practice.
[46] James D. Brenton,et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.
[47] R. Strausberg,et al. Serial circulating tumor DNA (ctDNA) and recurrence risk in patients (pts) with resectable colorectal liver metastasis (CLM). , 2016 .
[48] M. Choti,et al. Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.
[49] Dan Jackson,et al. Extending DerSimonian and Laird's methodology to perform multivariate random effects meta‐analyses , 2009, Statistics in medicine.
[50] D. Forman,et al. Who to treat with adjuvant therapy in Dukes B/stage II colorectal cancer? The need for high quality pathology , 2007, Gut.
[51] J. Meyerhardt,et al. Adjuvant Treatment of Colorectal Cancer , 2007, CA: a cancer journal for clinicians.
[52] M. Buyse,et al. Adjuvant therapy of colorectal cancer. Why we still don't know. , 1988, JAMA.
[53] M. Heuser,et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party , 2021 .